gsk679586

GSK679586 is a humanized anti-IL-13 IgG1 monoclonal antibody developed by GlaxoSmithKline (now GSK) for the treatment of severe asthma. It functions as an immunomodulator by specifically binding to interleukin-13 (IL-13), a cytokine implicated in asthma pathology. The drug was investigated for its ability to inhibit IL-13 binding to both IL-13 receptor α1 and α2, aiming to reduce pulmonary inflammation and improve asthma control in patients refractory to high-dose inhaled corticosteroids[2][3][6]. Clinical trials demonstrated that while GSK679586 was well tolerated and showed dose-dependent pharmacological activity in mild intermittent asthmatics—reducing markers of lung inflammation such as exhaled nitric oxide—it did not achieve clinically meaningful improvements in asthma control or pulmonary function in severe asthmatics[3][6]. Development for severe asthma has been discontinued[2].